ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1604

Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry

Maria I. Danila1, Kelly Gavigan2, Esteban Rivera2, Michael George3, Jeffrey Curtis4, William Nowell2 and Shilpa Venkatachalam2, 1University of Alabama at Birmingham, Birmingham, AL, 2Global Healthy Living Foundation, Upper Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, COVID-19, Disparities

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: COVID-19 vaccine confidence is key to promoting vaccination efforts to mitigate the spread of COVID-19 among people with rheumatic diseases. The goal of this study was to examine concerns and beliefs about COVID-19 vaccination among patients with rheumatic diseases enrolled in a national patient registry and to determine if education level is associated with COVID-19 vaccine confidence.

Methods: Members of the national ArthritisPower patient research registry were invited to complete an online survey. Vaccination confidence was evaluated using 1-item confidence scale from the validated 5C scale (range 1 = strongly disagree to 7 = strongly agree, higher values are better). Descriptive statistics summarized demographic characteristics, receipt of and concerns and beliefs about COVID-19 vaccination. Multiple regression assessed whether education is associated with vaccine confidence after adjusting for the effect of age, sex, and race and ethnicity (Model 1), age and sex (Model 2), and age (Model 3). Individuals who self-reported being Hispanic, non-Hispanic Black and non-Hispanic other race were grouped together as race and ethnic minority group.

Results: Between February 9 and March 24, 2021, we received 1345 responses. Mean (standard deviation) age was 59 (11.5) years, 86% were female, 87% were non-Hispanic white (Table 1). While 54% stated they had been offered a COVID-19 vaccine, only 42% had received at least one dose of the vaccine (Table 2). Among those unvaccinated, almost 18% said they were unlikely to get vaccinated. The most common reasons for not getting the vaccine were use of immunosuppressive medications (52%), concerns of disease flare (51%), fear of side effects (31%), prior reactions to other vaccines (21%), fears about the vaccine modifying one’s DNA (16%). While deliberating about vaccination, the following information was thought to be important: long-term efficacy of the vaccine (63%), side effects of the vaccine (63%) and its efficacy (52%) among people with the same health condition as the respondent. Compared to vaccinated people, unvaccinated persons had significantly lower scores on the confidence scales [6.3 (1.2) vs 4.5 (2.2), p< 0.01]. After controlling for age, sex, and race, lower level of education was associated with lower vaccine confidence (Table 3).

Conclusion: During the initial COVID-19 vaccine roll out, a substantial minority of patient members of a large national patient registry had received COVID-19 vaccination. Approximately 1 in 10 said they were unlikely to get vaccinated, even among this highly engaged and research-interested patient population. The main reasons for not getting the vaccine were use of immunosuppressive medications and concerns about a disease flare. Respondents felt they needed more information about the safety and efficacy of the COVID-19 vaccine among people with their conditions. Lower education level was associated with lower vaccine confidence. These findings highlight the need for developing COVID-19 vaccination campaigns that are tailored to different levels of education for people with rheumatic diseases.


Disclosures: M. Danila, Pfizer, 5, Pfizer, 11, AbbVie, 1, Amgen, 5, Amgen, 1, Boehringer Ingelheim, 5, Horizon, 5, WebMD, 12, writer, Novartis, 1; K. Gavigan, Global Healthy Living Foundation, 3; E. Rivera, None; M. George, None; J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5; W. Nowell, Global Healthy Living Foundation, 3, AbbVie, 5, Amgen, 5, Eli Lilly, 5; S. Venkatachalam, None.

To cite this abstract in AMA style:

Danila M, Gavigan K, Rivera E, George M, Curtis J, Nowell W, Venkatachalam S. Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/perceptions-about-covid-19-vaccination-among-patients-with-rheumatic-diseases-enrolled-in-a-national-patient-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/perceptions-about-covid-19-vaccination-among-patients-with-rheumatic-diseases-enrolled-in-a-national-patient-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology